ATE269103T1 - Stabilisierte wässerige glukagonlösungen enthaltend detergenzien - Google Patents

Stabilisierte wässerige glukagonlösungen enthaltend detergenzien

Info

Publication number
ATE269103T1
ATE269103T1 AT99906095T AT99906095T ATE269103T1 AT E269103 T1 ATE269103 T1 AT E269103T1 AT 99906095 T AT99906095 T AT 99906095T AT 99906095 T AT99906095 T AT 99906095T AT E269103 T1 ATE269103 T1 AT E269103T1
Authority
AT
Austria
Prior art keywords
solutions containing
stabilized aqueous
containing detergents
glucagon solutions
aqueous glucagon
Prior art date
Application number
AT99906095T
Other languages
English (en)
Inventor
Niels C Kaarsholm
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/DK1999/000115 external-priority patent/WO1999047160A1/en
Application granted granted Critical
Publication of ATE269103T1 publication Critical patent/ATE269103T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
AT99906095T 1998-03-13 1999-03-08 Stabilisierte wässerige glukagonlösungen enthaltend detergenzien ATE269103T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98610006 1998-03-13
PCT/DK1999/000115 WO1999047160A1 (en) 1998-03-13 1999-03-08 Stabilized aqueous peptide solutions

Publications (1)

Publication Number Publication Date
ATE269103T1 true ATE269103T1 (de) 2004-07-15

Family

ID=32524325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906095T ATE269103T1 (de) 1998-03-13 1999-03-08 Stabilisierte wässerige glukagonlösungen enthaltend detergenzien

Country Status (3)

Country Link
US (1) US6384016B1 (de)
AT (1) ATE269103T1 (de)
DE (1) DE69918070T2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522099A (ja) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
JP2003523366A (ja) 2000-01-27 2003-08-05 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド１化合物の可溶化方法
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
WO2004035623A2 (en) 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
EP2292254A3 (de) * 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilisierte pharmazeutische Peptidzusammensetzungen
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
PT3300721T (pt) * 2003-11-20 2019-06-06 Novo Nordisk As Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção
EP1789434B1 (de) * 2004-08-31 2013-11-20 Novo Nordisk A/S Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
AU2005303777B2 (en) * 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
WO2007007982A2 (en) * 2005-07-07 2007-01-18 Postech Foundation Glucose uptake modulator and method for treating diabetes or diabetic complications
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
BR112012011128A2 (pt) 2009-11-13 2016-07-05 Sanofi Aventis Deutschland composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
KR101823320B1 (ko) 2010-08-30 2018-01-31 사노피-아벤티스 도이칠란트 게엠베하 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
DK2875043T3 (en) 2012-07-23 2017-03-27 Zealand Pharma As glucagon
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
CA2973099C (en) 2015-01-12 2021-09-14 Enteris Biopharma, Inc. Solid oral dosage forms
MA52253A (fr) 2015-02-17 2021-02-17 Lilly Co Eli Formulation de poudre nasale pour le traitement de l'hypoglycémie
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
AU2017277590A1 (en) 2016-06-07 2019-01-24 Adocia Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
CN110088125B (zh) 2016-12-09 2023-10-03 西兰制药公司 酰化的glp-1/glp-2双重激动剂
PL3630806T3 (pl) 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
EP3474820B1 (de) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1-zusammensetzungen und verwendungen davon
CN111683675A (zh) 2017-12-07 2020-09-18 阿道恰公司 包含人胰高血糖素和共聚氨基酸的呈可注射水溶液形式的组合物
MX2020005915A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3083087A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
EP3720471B1 (de) 2017-12-07 2023-11-29 Adocia Zusammensetzungen in form einer injizierbaren wässrigen lösung mit menschlichem glucagon und einer copolyaminosäure
FR3067247A1 (fr) 2018-06-07 2018-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides

Also Published As

Publication number Publication date
DE69918070D1 (de) 2004-07-22
US6384016B1 (en) 2002-05-07
DE69918070T2 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
ATE269103T1 (de) Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
RU97118224A (ru) Соединения и композиции для доставки активных агентов
TW200626613A (en) Analogues of GLP-1
DK1629849T3 (da) Farmaceutiske sammensætninger indeholdende exendiner og deres agonister
HUP9904596A1 (hu) Mellékpajzsmirigy-hormon analógok
CO4750807A1 (es) Solucion de interferon
DE69736791D1 (de) Architecture de programmation d'un circuit avec memoire rom et memoire flash
DK1140018T3 (da) Polyol/olie-suspensioner til vedvarende frigørelse af proteiner
MY126897A (en) Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
NL1010890A1 (nl) Stabilisatormengsel.
ES2052488T3 (es) Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante.
IT1240314B (it) Formulazioni acquose stabilizzate di piccoli peptidi.
NO911861D0 (no) Stabilisert fgf-sammensetning.
ATE288471T1 (de) Flüssige reinigungs- oder waschmittelzusammensetzung
ATE214698T1 (de) Neue carbamazepin hapten analoge
HRP20010238B1 (en) 2-methyl-thieno-benzodiazepine formulation
PH31076A (en) Surfactant blends for detergent compositions.
DE59402088D1 (de) Ultramilde tensidmischungen
ATE129742T1 (de) Reinigungsmittelzusammensetzungen mit eigener selbstverdickungsfähigkeit.
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
BR9816029A (pt) Composições detergente
NO913919L (no) Vandig, tiksotropisk vaskemiddelblanding.
DZ1781A1 (fr) Agents d'arylation.
MA24608A1 (fr) Compositions contenant un sensibilisant a l'insuline, un secretagogue d'insuline et un agent anti-heperglycemique inhibiteur d'alphat-glugosidase.
DE59401867D1 (de) Ultramilde tensidmischungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties